Loading investment pitches...
Equity Research Database
Institutional Investment Pitches
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Explore thousands of hedge fund pitches, high-conviction equity research memos, and portfolio manager commentary extracted from quarterly letters.
Bought shares. Repligen is a...
— Neal Kaufman
Full equity research memos, financial breakdowns, and hedge fund thesis write-ups are reserved for BSD Research ($50/mo) and Pro subscribers.
Already a Research or Pro subscriber? Sign In
Other investors who've written on Repligen Corporation
Repligen Corporation is positioned to benefit from numerous company-specific tailwinds in 2025, making it a compelling investment in the bioprocessing space. Despite...
Repligen Corporation recently announced a strategic acquisition of BioLife Solutions to expand its capabilities in the cell therapy market. The deal, valued...
More institutional theses from Baron Health Care Fund
Eli Lilly and Company ($LLY) is a global pharmaceutical leader specializing in treatments for diabetes, obesity, oncology, and immunology, representing the Fund's largest portfolio holding at 14.3% of net assets. The manager maintains...
Thermo Fisher Scientific Inc. ($TMO) is the world's premier provider of life sciences tools, laboratory supplies, analytical instruments, and clinical trial services, representing 5.9% of fund assets. The investment manager...
Xenon Pharmaceuticals Inc. ($XENE) is a clinical-stage biopharmaceutical developer focused on novel ion channel therapies for neurological disorders. The manager adopted...